234 related articles for article (PubMed ID: 28386776)
1. Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections.
Stewart CL; Turner MS; Frens JJ; Snider CB; Smith JR
Infect Dis Ther; 2017 Jun; 6(2):277-289. PubMed ID: 28386776
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
[TBL] [Abstract][Full Text] [Related]
3. Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections.
Brade KD; Rybak JM; Rybak MJ
Infect Dis Ther; 2016 Mar; 5(1):1-15. PubMed ID: 26831328
[TBL] [Abstract][Full Text] [Related]
4. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
Das B; Sarkar C; Schachter J
Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study.
Van Hise NW; Chundi V; Didwania V; Anderson M; McKinsey D; Roig I; Sharma A; Petrak RM
Drugs Real World Outcomes; 2020 Jun; 7(Suppl 1):41-45. PubMed ID: 32588385
[TBL] [Abstract][Full Text] [Related]
6. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
Corey GR; Arhin FF; Wikler MA; Sahm DF; Kreiswirth BN; Mediavilla JR; Good S; Fiset C; Jiang H; Moeck G; Kabler H; Green S; O'Riordan W;
Int J Antimicrob Agents; 2016 Nov; 48(5):528-534. PubMed ID: 27665522
[TBL] [Abstract][Full Text] [Related]
7. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
8. Oritavancin as sequential therapy for Gram-positive bloodstream infections.
Texidor WM; Miller MA; Molina KC; Krsak M; Calvert B; Hart C; Storer M; Fish DN
BMC Infect Dis; 2024 Jan; 24(1):127. PubMed ID: 38267844
[TBL] [Abstract][Full Text] [Related]
9. Oritavancin: a long-acting antibacterial lipoglycopeptide.
Kaasch AJ; Seifert H
Future Microbiol; 2016 Jul; 11():843-55. PubMed ID: 27161039
[TBL] [Abstract][Full Text] [Related]
10. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
11. Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections.
Mitra S; Saeed U; Havlichek DH; Stein GE
Infect Drug Resist; 2015; 8():189-97. PubMed ID: 26185459
[TBL] [Abstract][Full Text] [Related]
12. Oritavancin: an investigational lipoglycopeptide antibiotic.
Karaoui LR; El-Lababidi R; Chahine EB
Am J Health Syst Pharm; 2013 Jan; 70(1):23-33. PubMed ID: 23261897
[TBL] [Abstract][Full Text] [Related]
13. Oritavancin for acute bacterial skin and skin structure infections.
Messina JA; Fowler VG; Corey GR
Expert Opin Pharmacother; 2015 May; 16(7):1091-8. PubMed ID: 25803197
[TBL] [Abstract][Full Text] [Related]
14. Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010-2016): concomitant analysis of oritavancin in vitro activity.
Mendes RE; Sader HS; Castanheira M; Flamm RK
J Chemother; 2018 Sep; 30(5):280-289. PubMed ID: 30843778
[TBL] [Abstract][Full Text] [Related]
15. Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.
Jones RN; Turnidge JD; Moeck G; Arhin FF; Mendes RE
Antimicrob Agents Chemother; 2015 Apr; 59(4):2405-9. PubMed ID: 25666152
[TBL] [Abstract][Full Text] [Related]
16. Role of Oritavancin in the Treatment of Infective Endocarditis, Catheter- or Device-Related Infections, Bloodstream Infections, and Bone and Prosthetic Joint Infections in Humans: Narrative Review and Possible Developments.
Lupia T; De Benedetto I; Bosio R; Shbaklo N; De Rosa FG; Corcione S
Life (Basel); 2023 Apr; 13(4):. PubMed ID: 37109488
[TBL] [Abstract][Full Text] [Related]
17. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
[TBL] [Abstract][Full Text] [Related]
18. Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis.
Johnson JA; Feeney ER; Kubiak DW; Corey GR
Open Forum Infect Dis; 2015 Dec; 2(4):ofv156. PubMed ID: 26677455
[TBL] [Abstract][Full Text] [Related]
19. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin.
Mohan SS; McDermott BP; Cunha BA
Heart Lung; 2005; 34(1):69-71. PubMed ID: 15647736
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review.
Chastain DB; Davis A
Int J Antimicrob Agents; 2019 Apr; 53(4):429-434. PubMed ID: 30537532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
